All Stories

  1. Long-Term Efficacy of Dupilumab in Quadrants of Elevated- vs Low- Type 2 Biomarker Patients With Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA TRAVERSE
  2. When less is more in asthma management
  3. A tail of two diagnoses: Supporting patients with both COPD and Cardiovascular risks
  4. A structured review of the ASCENT Study for COPD
  5. Efficacy of MF/IND/GLY to reduce asthma exacerbation
  6. Pooled data from PALLADIUM and IRIDIUM studies- The impact of Breezhaler® once daily
  7. The cause of COPD is not always smoking history.
  8. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
  9. The experience of asthma from the patient and physicians
  10. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
  11. The survey for Asthma Patients’ and Physicians’ Perspectives on the Burden and Management of Asthma
  12. The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial
  13. The Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and the Heterogeneity of Risk Factors in the Canadian Population: Results from the Canadian Obstructive Lung Disease (COLD) Study
  14. A review of the past, present and future for Alpha-1 Antitrypsin Deficiency
  15. Reducing the hidden burden of severe asthma: recognition and referrals from primary practice
  16. Working smarter to improve asthma care
  17. Status of Severe Asthma Management in Canada
  18. Treatment of Asthma with Breezhaler
  19. Long term impacts of tobacco and marijuana smoking on lung function
  20. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD
  21. Improving maintenance treatment for COPD patients
  22. COPD exacerbation rates with IND/GLY
  23. An update on Alpha 1 antitrypsin deficiency
  24. Self-Management and Clinical Decision Support for Patients With Complex Chronic Conditions Through the Use of Smartphone-Based Telemonitoring: Randomized Controlled Trial Protocol
  25. A review of COPD from the 2015 European Respiratory Society Congress
  26. Safety of Breezhaler® device
  27. The prevalence of asthma and atopy in schoolchildren from Porto Alegre, Brazil, has plateaued
  28. Clinical Relevance of Fixed Ratio vs Lower Limit of Normal of FEV1/FVC in COPD: Patient-Reported Outcomes From the CanCOLD Cohort
  29. Exacerbations in non-COPD patients: truth or myth—authors’ response
  30. Quality Assurance of Spirometry in a Population-Based Study –Predictors of Good Outcome in Spirometry Testing
  31. Comparing the standard COPD drug treatment to a new drug: Tiotropium VS. Glycopyrronium
  32. Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in five European countries
  33. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study
  34. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study
  35. Do We Know the Minimal Clinically Important Difference (MCID) for COPD Exacerbations?
  36. Bronchodilator Responsiveness and Reported Respiratory Symptoms in an Adult Population
  37. Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
  38. Asthma controller delay and recurrence risk after an emergency department visit or hospitalization
  39. What Do We Know about Asthma Triggers? A Review of the Literature
  40. A Step Forward in COPD Management
  41. Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease
  42. The Association Between Chronic Exposure to Traffic-Related Air Pollution and Ischemic Heart Disease
  43. Profile of eicosanoids in breath condensate in asthma and COPD
  44. Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD
  45. Improved outcomes and adherence with novel COPD treatment: Indacaterol
  46. Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor
  47. The SMART treatment for asthma isn't as smart as it seems
  48. Can age and sex explain the variation in COPD rates across large urban cities? A population study in Canada
  49. Long-term Safety and Efficacy of Indacaterol, a Long-Acting β 2 -Agonist, in Subjects With COPD
  50. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD
  51. Nontuberculous Mycobacterial Infection as a Cause of Difficult-to-Control Asthma
  52. Infection with Mycoplasma pneumoniae is not related to asthma control, asthma severity, and location of airway obstruction
  53. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study
  54. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal
  55. Dynamic Airway Evaluation with Volume CT: Initial Experience
  56. Low-dose fluticasone propionate with and without salmeterol in steroid-naïve patients with mild, uncontrolled asthma
  57. SMART isn't
  58. Asthma that is unresponsive to usual care